Cerity Partners’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Buy |
176,938
+31,699
| +22% | +$2.11M | 0.01% | 675 |
|
|
2026
Q1 | $9.12M | Buy |
145,239
+7,253
| +5% | +$505K | 0.01% | 739 |
|
|
2025
Q4 | $9.16M | Buy |
137,986
+17,571
| +15% | +$1.14M | 0.01% | 679 |
|
|
2025
Q3 | $8.1M | Buy |
120,415
+60,241
| +100% | +$4.77M | 0.01% | 667 |
|
|
2025
Q2 | $5.25M | Sell |
60,174
-9,427
| -14% | -$739K | 0.01% | 784 |
|
|
2025
Q1 | $4.75M | Buy |
69,601
+2,711
| +4% | +$221K | 0.01% | 752 |
|
|
2024
Q4 | $5.1M | Buy |
66,890
+6,840
| +11% | +$506K | 0.01% | 705 |
|
|
2024
Q3 | $4.03M | Buy |
60,050
+39,344
| +190% | +$3.23M | 0.01% | 796 |
|
|
2024
Q2 | $2.35M | Sell |
20,706
-5,578
| -21% | -$705K | 0.01% | 846 |
|
|
2024
Q1 | $3.65M | Sell |
26,284
-437,689
| -94% | -$55M | 0.01% | 758 |
|
|
2023
Q4 | $1.4M | Buy |
463,973
+456,097
| +5,791% | +$46.6M | ﹤0.01% | 880 |
|
|
2023
Q3 | $735K | Sell |
7,876
-8,705
| -52% | -$981K | ﹤0.01% | 847 |
|
|
2023
Q2 | $2.13M | Buy |
16,581
+3,673
| +28% | +$444K | 0.01% | 713 |
|
|
2023
Q1 | $1.5M | Buy |
12,908
+155
| +1% | +$17.4K | ﹤0.01% | 814 |
|
|
2022
Q4 | $1.44M | Buy |
12,753
+5,338
| +72% | +$586K | 0.01% | 600 |
|
|
2022
Q3 | $597K | Sell |
7,415
-288
| -4% | -$24.4K | 0.01% | 647 |
|
|
2022
Q2 | $575K | Buy |
7,703
+1,911
| +33% | +$174K | 0.01% | 704 |
|
|
2022
Q1 | $743K | Sell |
5,792
-2,248
| -28% | -$246K | 0.01% | 498 |
|
|
2021
Q4 | $1.08M | Buy |
8,040
+2,608
| +48% | +$375K | 0.02% | 428 |
|
|
2021
Q3 | $743K | Sell |
5,432
-132
| -2% | -$16.6K | 0.02% | 399 |
|
|
2021
Q2 | $594K | Buy |
5,564
+64
| +1% | +$6.15K | 0.01% | 441 |
|
|
2021
Q1 | $494K | Buy |
5,500
+692
| +14% | +$65K | 0.01% | 450 |
|
|
2020
Q4 | $444K | Buy |
4,808
+36
| +0.8% | +$3.21K | 0.01% | 433 |
|
|
2020
Q3 | $492K | Buy |
4,772
+1,368
| +40% | +$143K | 0.02% | 324 |
|
|
2020
Q2 | $345K | Sell |
3,404
-424
| -11% | -$37.9K | 0.02% | 330 |
|
|
2020
Q1 | $258K | Buy |
3,828
+28
| +0.7% | +$1.74K | 0.02% | 370 |
|
|
2019
Q4 | $208K | Buy |
+3,800
| New | +$180K | 0.01% | 496 |
|
|
2019
Q1 | – | Sell |
-9,592
| Closed | -$287K | – | 541 |
|
|
2018
Q4 | $287K | Buy |
9,592
+3,920
| +69% | +$124K | 0.02% | 411 |
|
|
2018
Q3 | $203K | Buy |
+5,672
| New | +$176K | 0.01% | 511 |
|
Other funds holding DXCM
Cerity Partners's DXCM Position: Q2 2026 in Review
Cerity Partners increased its DexCom (DXCM) stake by 22% in Q2 2026, buying an estimated $2.11M and bringing the position to 176,938 shares worth $11.9M. The position accounts for 0.01% of the portfolio, ranked #675.
Cerity Partners first reported a position in DXCM in Q3 2018 and has held it in 29 quarters since. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Cerity Partners held 176,938 shares of DexCom worth $11.9M as of Q2 2026.
- Cerity Partners bought 31,699 DexCom shares in Q2 2026, an estimated $2.11M.
- DexCom made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #675 holding.
- Cerity Partners first reported a position in DexCom in Q3 2018 and has held it in 29 quarters since.
- 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.